Abstract
This commentary discusses a small multicenter, prospective clinical trial in which patients with end-stage renal disease were randomized to treatment with online high-flux hemofiltration or low-flux hemodialysis. Over a 3-year follow-up period, survival was significantly better in patients who received online hemofiltration than in patients who received low-flux hemodialysis. In addition, the average duration, but not the frequency, of hospitalization, and the incidence of intradialytic hypotension, were lower in the hemofiltration group than in the hemodialysis group. The study supports the hypothesis that increased removal of large molecules can decrease the high morbidity and mortality associated with end-stage renal disease. However, the applicability of the findings to the general population of patients with end-stage renal disease might be limited by the small size of the study, the demographics of the study population, and the high dropout rate. Larger trials are needed to confirm this study's results and to establish the appropriate dose of convection for optimal outcomes.
References
Eknoyan G et al. (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019
Santoro A et al. (2008) The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 52: 507–518
van Kuijk WH et al. (1997) Critical role of the extracorporeal blood temperature in the hemodynamic response during hemofiltration. J Am Soc Nephrol 8: 949–955
Vanholder R et al. (2008) Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. NDT Plus 1: 2–10
Canaud B et al. (2006) Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 69: 2087–2093
Marshall MR et al. (2006) Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 69: 1229–1236
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has declared associations with the following companies: Fresenius, as a consultant, Gambro, as a consultant and recipient of grant/research support, and Rockwell Medical Technologies, as recipient of grant/research support.
Rights and permissions
About this article
Cite this article
Ward, R. Does increased removal of high-molecular-weight toxins improve the survival of hemodialysis patients?. Nat Rev Nephrol 5, 14–15 (2009). https://doi.org/10.1038/ncpneph1002
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph1002
- Springer Nature Limited